ReviewAAPS PharmSciTech2025
Efficacy of Novel Drug Delivery Systems for Insulin Administration and Technological Advances in Diabetes Mellitus: Review.
Review in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a clinical syndrome characterized by disturbance in carbohydrate, fat and protein metabolism due to either insulin deficiency or insulin resistance. Oral medications and insulin injections have typically been the conventional delivery modalities of diabetes treatment for both type 1 and patients with advanced type 2 diabetes. In spite of this, these treatments have some drawbacks, including low efficacy, unwanted side effects and the possibility of hypoglycemia. New developments in medication delivery techniques, such as insulin pumps, inhalers and patches, have been made with the intention of enhancing the efficacy of the treatment. Insulin pumps allow for precise and flexible administration of insulin, which, in turn, reduces the number of episodes of low blood sugar. The use of inhalers provides a non-invasive alternative that facilitates rapid glycemic management and increases patient satisfaction. Currently in the process of being developed, insulin patches provide a means of administering insulin that is both simple and painless. In this review, we investigate the efficacy, safety and practicability of various technological breakthroughs, such as insulin pumps, smart insulin pens and continuous glucose monitoring systems. In addition to this, it addresses the challenges that are preventing a wider acceptance, such as the costs, the availability and the requirements for training. In order to enhance patient outcomes and usher in a new era of diabetes care that is increasingly driven by technology, the report places a strong emphasis on the necessity of continued research and innovation.
Indexed as
Identifiers
41350796What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.